(3aR,6aS)-5-tert-butyl-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡咯
• 英文名称: (3aR,6aS)-5-tert-butyl-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrole
• 化学式: C₁₀H₁₉NO
• 分子量: 169.26
• InChiKey: MUPOZZMPZSZVOF-DTORHVGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20140228361A1

  公开（公告）日：2014-08-14

  The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明涉及医学领域。本文提供了氨基喹唑啉衍生物，其盐和药物配方在调节蛋白酪氨酸激酶活性以及调节细胞间和/或细胞内信号传导方面具有用处。本文还提供了包含氨基喹唑啉化合物的药用可接受组合物，以及在治疗哺乳动物，特别是人类的增生性疾病中使用这些组合物的方法。
• AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20160039838A1

  公开（公告）日：2016-02-11

  Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.

  本文提供了氨基喹啉化合物、盐及其用途。该化合物具有式(I)、立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或其前药。本文还提供了含有上述化合物的制药组合物，并使用该化合物或组合物预防、管理、治疗或减轻患者的增生性疾病严重程度，并调节蛋白酪氨酸激酶活性。
• Fumagillol heterocyclic compounds and methods of making and using same
  申请人：Zafgen, Inc.

  公开号：US10023561B2

  公开（公告）日：2018-07-17

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文部分公开了烟曲霉素化合物和用于治疗肥胖等疾病的方法。提供了药物组合物和制造烟嘧酚化合物的方法。这些化合物对蛋氨酰氨基肽酶 2 具有活性。
• Substituted 6-azabenzimidazole compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11203591B2

  公开（公告）日：2021-12-21

  The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

  本公开一般涉及某些 6-氮杂苯并咪唑化合物、包含所述化合物的药物组合物以及制造和使用所述化合物和药物组合物的方法。本文公开的化合物和组合物可用于治疗或预防可被造血祖细胞激酶 1（HPK1）抑制剂改变的疾病、失调或感染，如 HBV、HIV、癌症和/或过度增殖性疾病。
• FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME
  申请人：Zafgen, Inc.

  公开号：US20170342058A1

  公开（公告）日：2017-11-30

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.